All In Biotech

Drug Trial Radar · NCT07940881

A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors

SI-B037-ST-101: A Multicenter, Open-Label, Phase 1/1b, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SI-B037 in Adult Patients With Advanced/Metastatic Solid Tumors That Are Refractory to Standard Therapies

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 24, 2026

Primary completion

Nov 2028

Study completion Nov 2029

Sponsor

Lead sponsor
SystImmune Inc.Industry
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.

Conditions

  • Locally Advanced /Metastatic Solid Tumors
  • Locally Advanced / Metastatic Solid Tumors
  • First in Human
  • Metastatic Solid Cancers
  • Non Small Cell Lung Cancer
  • NSCLC
  • Lung Cancer (Diagnosis)
  • Lung Cancer (NSCLC)
  • Lung Cancer (Non-Small Cell)
  • Lung Cancer (Locally Advanced or Metastatic)
  • Melanoma (Skin Cancer)
  • Ovarian Cancer
  • Phase 1
  • Phase 1 Clinical Trial
  • Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC)

Interventions

  • SI-B037Drug

    SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants with Dose-Limiting ToxicitiesTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NEXT Oncology

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.